相关实验视频
Updated: Jan 17, 2026

05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
909
超重或肥胖的人群中肥胖药物治疗前景
John W Ostrominski1,2,3, Anindit Chhibber4, Effie L Kuti4
1Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Patient preference and adherence
|September 19, 2025
概括
使用肥胖药物 (OMs) 的患者,特别是GLP-1受体激活剂 (GLP-1RAs),报告了积极的体验和健康改善. 主要障碍包括成本和保险,强调需要更好地获得和沟通关于长期肥胖治疗的需求.
科学领域:
- 肥胖药物治疗药物治疗方法
- 患者报告的结果.
- 现实世界的证据.
背景情况:
- 肥胖是一种复杂的慢性疾病,对健康有重大影响.
- 肥胖药物 (OMs),包括GLP-1受体激动剂 (GLP-1RAs),提供临床益处,但实际患者的经验没有得到充分记录.
- 了解患者行为和OMs的财务影响对于优化治疗至关重要.
研究的目的:
- 评估患者的行为和对肥胖药物 (OMs) 的经验.
- 评估OMs对患者的财务影响.
- 确定启动和接受肥胖药物治疗的关键决策点.
主要方法:
- 进行了一项在线调查,对100名肥胖的成年人 (BMI≥30 kg/m2或≥27 kg/m2并发症) 目前使用OMs.
- 参与者报告了OM使用的动机,障碍,挑战,医疗保健提供者 (HCP) 互动以及OM使用的财务方面.
- 数据是在2024年7月8日至18日期间从通过国家数据库招募的个人中收集的.
主要成果:
- 大多数参与者 (91%) 使用了GLP-1RA,并且之前曾尝试过减肥.
- 主要驱动OM启动的因素是健康改善 (58%) 和功能增强 (53%).
- 主要障碍包括保险限制 (38%),副作用问题 (37%) 和成本 (31%). 88%的人报告了积极的经验,特别是治疗时间较长 (≥6个月).
结论:
- 患者对OM的经验是多方面的,积极的结果通常与更长的治疗持续时间有关.
- 解决成本,保险和耻辱等障碍对于最大限度地提高肥胖药物治疗的有效性至关重要.
- 需要加强患者与医疗服务提供者的沟通,以提高治疗持续时间和生活方式的整合.
相关概念视频
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
248
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
248
Drug Dosing: Obese Patients
225
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
225
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
169
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
169
Obesity
1.1K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
Antidepressant Drugs: MAOIs and Other Agents
828
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
828
Diabetes: Management and Pharmacotherapy
868
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
868

